Skip to main content
. 2011 Jul 12;118(8):2062–2068. doi: 10.1182/blood-2011-01-329177

Table 5.

A comparison of key features of patients with 17p deletion treated with CFAR versus historic high-risk group treated with FCR

Parameter CFAR (n = 14) FCR (n = 18)
CR 57%* 17%*
ORR 79% 67%
Median PFS 15 mo 12 mo
Median OS 25+ mo 55 mo

FCR indicates fludarabine, cyclophosphamide, and rituximab; CFAR, alemtuzumab added to FCR; CR, complete remission; ORR, overall response rate; PFS, progression-free survival; and OS, overall survival.

*

Fisher exact, 2-tailed test P = .03.